Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tygacil Hospital Antibiotic Launch Expected Within 12 Months

This article was originally published in The Pink Sheet Daily

Executive Summary

Wyeth hopes to launch the injectable antibiotic Tygacil (tigecycline) within the next 12 months, CEO Robert Essner told the Bear Stearns conference in New York Sept. 14.

You may also be interested in...

Wyeth Touts Tygacil As First Global NDA Submission

The first-in-class glycylcycline antibiotic could be a monotherapy option in the treatment of complicated infections, Wyeth says. The company would likely detail the injectable alongside its antibiotic Zosyn.

After ODAC: The State Of Accelerated Approval At The US FDA

US FDA’s Accelerated Approval process has always been a deceptively simple idea. After a three-day public review of ‘dangling’ applications, the underlying complexity remains.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts